Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Nutrition Continues Launches Despite Divestment Possibility

This article was originally published in The Tan Sheet

Executive Summary

Pfizer remains active in its international nutritionals business with the launch of an expanded line of pediatric products, even as the company considers divesting the nutrition unit.
Advertisement

Related Content

Nestle To Become No. 1 In China's Infant Formula Market Following Pfizer Nutrition Acquisition
Nestle To Become No. 1 In China's Infant Formula Market Following Pfizer Nutrition Acquisition
Pfizer CEO Read Expects Gradual Plans For Change In Second Half 2011
Pfizer CEO Read Expects Gradual Plans For Change In Second Half 2011
Pfizer CEO Read Expects Gradual Plans For Change In Second Half 2011
Freed From Pfizer, Capsugel May Find More Market Opportunities
Freed From Pfizer, Capsugel May Find More Market Opportunities
Pfizer Buys Ferrosan Consumer Unit, Expands In Russia And Northern Europe

Topics

Advertisement
UsernamePublicRestriction

Register

PS105024

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel